Status:

COMPLETED

18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Lead Sponsor:

Sanofi

Conditions:

Alzheimer Disease

Eligibility:

All Genders

50+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patient...

Eligibility Criteria

Inclusion

  • Diagnosis of probable Alzheimer's disease using NINCDS-ADRDA criteria
  • Mild to moderate degree of severity of dementia as assessed by the Mini-Mental State Examination score of 16 to 26 (inclusive)
  • Potential participant may be treated with conventional Alzheimer's disease therapy and must be on stable dose for at least 6 months prior to the randomization and during the entire study period
  • Potential participant must have a reliable caregiver and must be living in a community or in an assisted living facility
  • Mother tongue is English, Spanish or French (oral and written fluency)
  • Signed informed consent from potential participant or legal representative and identified caregiver

Exclusion

  • Potential participant with any other cause of dementia.
  • Potential participant with serious health problems other than Alzheimer's disease
  • Use of an investigational drug within two months prior to randomization or during this study

Key Trial Info

Start Date :

November 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2007

Estimated Enrollment :

1306 Patients enrolled

Trial Details

Trial ID

NCT00103649

Start Date

November 1 2003

End Date

October 1 2007

Last Update

August 21 2008

Active Locations (121)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 31 (121 locations)

1

UAB Memory Disorders Clinic

Birmingham, Alabama, United States, 35294-0017

2

Barrow Neurology Clinics

Phoenix, Arizona, United States, 85013

3

PsyPharma Clinical Research, Inc.

Phoenix, Arizona, United States, 85050

4

Radiant Research

Scottsdale, Arizona, United States, 85251